Moving from a scientific to a business-oriented outlook is an inherent challenge of the Pharma market. Which is why, many blockbuster drugs of Big Pharma Players have been licensed in from small Pharma players or academia centres of research universities, as the former entities have a great sense of business. Correctly called other’s science, these drugs receive a platform to perform exceptionally well in the market. Still, such licensing processes possess inherent challenges.
Here comes in our game-modifying role, where we assist either of the entities to find the other through our proprietary licensing service offering. Designed in such a way that we find- every time- the best strategic licensing partner for our clients. Having speciality of all therapeutic areas and networks across the globe, we are expertly positioned to provide the best consulting advice.
A large pharma client was working to develop their API and FD, and was interested to assess CDMO companies and their capabilities in this domain to provide benchmarking of the best company for outsourcing their project. [...]
A large client based in Europe involved DelveInsight to assist in assessing counter-intelligence strategies for them, after evaluation of their level of leakiness among middle and high-level employees. [...]
Request For Proposal